FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL				
OMB Number:	3235-0104			
Estimated average burden				
hours per response:	0.5			

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

			n 16(a) of the Securities Exchange Act of the Investment Company Act of 1940				
DIALECTIC CADITAL	2. Date of Event F Statement (Month 11/18/2022		3. Issuer Name and Ticker or Trading ACHIEVE LIFE SCIENCE		ACHV]		
MANAGEMENT, LP			Relationship of Reporting Person(s (Check all applicable)	s) to Issuer		Amendment, Date hth/Day/Year)	e of Original Filed
(Last) (First) (Middle) 119 ROWAYTON AVENUE 2ND FLOOR			Director X Officer (give title below)	10% Owner Other (specify below)		Form filed by	Oroup Filing (Check One Reporting Person More than One Reporting
(Street) NORWALK CT 06853						Feisuii	
(City) (State) (Zip)							
	Table I - No	on-Deriva	tive Securities Beneficially	Owned			
1. Title of Security (Instr. 4)			2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (I Indirect (I) (Ins	0) or 5)	ure of Indirect Bo	eneficial Ownership (Instr.
Common Stock, par value \$0.001 per share			3,494,000(3)	I	Ву: Г	ialectic Life S	ciences SPV LLC(1)
Common Stock, par value \$0.001 per share			55,000	I	By: Jo	By: John Fichthorn ⁽²⁾	
			ve Securities Beneficially Ov ants, options, convertible so				
1. Title of Derivative Security (Instr. 4)	2. Date Exercis Expiration Dat (Month/Day/Ye	е	3. Title and Amount of Securities Derivative Security (Instr. 4)	Underlying	4. Conversion or Exercise	(D) or	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Price of Derivative Security	nversion Exercise (D) or Indirect (I) (Instr. 5) By: Dialectic Life	
Common Stock Warrants (right to buy)	05/18/2023 ⁽⁴⁾⁽⁵⁾	11/18/2029	Common Stock	1,747,000(3)	4.5	I	By: Dialectic Life Sciences SPV LLC ⁽¹⁾
1. Name and Address of Reporting Person* <u>DIALECTIC CAPITAL MANAGEMENT</u>	<u>, LP</u>						
(Last) (First) (Middle) 119 ROWAYTON AVENUE 2ND FLOOR							
(Street)							
NORWALK CT 06853							

DIALLETIC	CAITTAL WAY	NAGENIENT, LI	_
(Last)	(First)	(Middle)	
119 ROWAYTO	N AVENUE		
2ND FLOOR			
(Street)			_
NORWALK	CT	06853	
(City)	(State)	(Zip)	_
		(_
	of Reporting Person*		
Dialectic Partr	iers, LLC		
(Last)	(First)	(Middle)	_
, ,	ROWAYTON AV	, ,	
			_
(Street)			
NORWALK	CT	06853	
			_
(City)	(State)	(Zip)	

1. Name and Address	s of Reporting Person *		
(Last)	(First)	(Middle)	
C/O DIALECTIO	C CAPITAL MANA	GEMENT, LP	
119 ROWAYTO	N AVENUE, 2ND	FLOOR	
(Street)			
NORWALK	CT	06853	
(City)	(State)	(Zip)	
1. Name and Address Dialectic LS M	s of Reporting Person* Manager LLC		
(Last)	(First)	(Middle)	
119 ROWAYTO 2ND FLOOR	N AVENUE		
(Street) NORWALK	СТ	06853	
(City)	(State)	(Zip)	
1. Name and Address	s of Reporting Person*		
Dialectic Life	Sciences SPV I	LC	
(Last)	(First)	(Middle)	
C/O DIALECTIO	C LS MANAGER L	LC	
119 ROWAYTO	N AVENUE, 2ND	FLOOR	
(Street)			
NORWALK	CT	06853	
(City)	(State)	(Zip)	

Explanation of Responses:

1. These securities are held directly by Dialectic Life Sciences SPV LLC (the "SPV"). The SPV is a private investment vehicle. Dialectic Capital Management LP (the "Adviser") is the investment adviser for the SPV. Dialectic Partners, LLC (the "Adviser GP") is the general partner of the Adviser. Dialectic LS Manager LLC (the "SPV MM") is the managing member of the SPV. John Fichthorn is the controlling person of the Adviser GP and the SPV MM. Each Reporting Person disclaims beneficial ownership of all securities reported herein, except to the extent of their pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities and Exchange Act of 1934 or for any other purpose.

- 2. These securities are held directly by John Fichthorn. Each Reporting Person disclaims beneficial ownership of all securities reported herein, except to the extent of their pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities and Exchange Act of 1934 or for any other purpose.
- 3. The reported securities are included within 1,747,000 ACHV Units purchased by the SPV on November 18, 2022. Each Unit consists of two shares of Common Stock and one warrant to purchase one share of Common Stock.
- 4. The Issuer shall not effect any exercise of these warrants, and the SPV shall not have the right to exercise these warrants, to the extent that after giving effect to the issuance of Common Stock after exercise, the SPV (together with the SPV's affiliates), and any other persons acting as a group together with the SPV or any of the SPV's affiliates) would beneficially own in excess of the Beneficial Ownership Limitation.
- 5. The "Beneficial Ownership Limitation" shall be 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of these warrants. The SPV, upon notice to the Issuer, may decrease, and subsequently increase or decrease, the Beneficial Ownership Limitation, provided that the Beneficial Ownership Limitation in no event exceeds 19.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of these warrants. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st day after notice is delivered to the Issuer.

/s/ John Fichthorn, for himself and as controlling person of the Adviser GP (for itself and on behalf of the Adviser) and the SPV MM (for itself and on behalf of the SPV)

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.